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Introduction
Mammalian epidermis functions as a barrier to prevent both 
water loss to the terrestrial environment and entry of toxic 
and pathogenic agents into the organism (Elias, 2005; Segre, 
2006). Embryonic ectoderm is specifi  ed to an epidermal fate at 
murine embryonic day (E) 8.5, regulated by the p63 transcrip-
tion factors (Koster and Roop, 2004). At E9.5, this single layer 
of basal cells express cytokeratin (K) 5 and K14 (Byrne et al., 
1994). During midembryogenesis, these basal cells continue 
to divide as a single-layered epithelium to increase the sur-
face area of the developing embryo. Stratifi  cation of the basal 
epithelium initiates at E12.5 with asymmetric cell divisions 
perpendicular to the basement membrane (Lechler and Fuchs, 
2005). By E15.5, suprabasal cells initiate the differentiation 
program and express K1/K10 (Byrne et al., 1994). Establish-
ment of the epidermal permeability barrier initiates at E16.5 
on the dorsal surface and spreads ventrally to achieve a fully 
competent barrier by E18 (Hardman et al., 1998). Barrier es-
tablishment requires cross-linking of the cells in the upper 
layer, which then constrains increases to the surface area of 
the embryo. Although the barrier must be acquired before the 
typical end of gestation, it is not advantageous to develop a 
fully competent barrier too early in development because of 
the need for continued growth.
Interfollicular epidermal cells retain the ability to self-
renew under both homeostatic and injured conditions by main-
taining mitotically active cells (Blanpain et al., 2004; Morris 
et al., 2004; Tumbar et al., 2004; Ito et al., 2005; Levy et al., 
2005). Terminal differentiation begins when basal cells con-
comitantly withdraw from the cell cycle and lose adhesion 
to the basement membrane. In the intermediate spinous   layers, 
the cells assemble a durable cytoskeletal framework that pro-
vides mechanical strength to resist physical trauma. In the 
upper granular layer, a cornifi  ed envelope (CE) is assembled 
directly underneath the plasma membrane by sequential in-
corporation of precursor proteins. Lipid-containing lamellar 
bodies fuse with the plasma membrane and attach to the CE 
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  S
kin lies at the interface between the complex physi-
ology of the body and the external environment. 
This essential epidermal barrier, composed of corni-
ﬁ  ed proteins encased in lipids, prevents both water loss 
and entry of infectious or toxic substances. We uncover that 
the transcription factor GATA-3 is required to establish the 
epidermal barrier and survive in the ex utero environment. 
Analysis of Gata-3 mutant transcriptional proﬁ   les at 
three critical developmental stages identiﬁ  es a speciﬁ  c 
defect in lipid biosynthesis and a delay in differentiation. 
Genomic analysis identiﬁ   es highly conserved GATA-3 
binding sites bound in vivo by GATA-3 in the ﬁ  rst intron of 
the lipid acyltransferase gene AGPAT5. Skin from both 
Gata-3−/− and previously characterized barrier-deﬁ  cient 
Kruppel-like factor 4−/− newborns up-regulate anti-
microbial peptides, effectors of innate immunity.   Comparison 
of these animal models illustrates how impairment of the 
skin barrier by two genetically distinct mechanisms leads 
to innate immune responses, as observed in the common 
human skin disorders psoriasis and atopic dermatitis.
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scaffold, sealing the now enucleated cells together to create the 
“bricks and mortar” barrier at the skin surface (Elias, 2005). 
Recent experimental results have also demonstrated a selec-
tive role for tight junctions in establishing the epidermal barrier 
(Furuse et al., 2002). This process of differentiation from a mi-
totically active basal cell to a terminally differentiated squame 
is maintained throughout life as part of epidermal regeneration 
and maturation.
Mouse models with targeted ablations of genes encoding 
keratinocyte transcription factors have demonstrated that bar-
rier acquisition is a coordinated and regulated process (Dai and 
Segre, 2004). Our earlier experiments demonstrated that the 
transcription factor Kruppel-like factor 4 (Klf4) is necessary to 
establish the epidermal barrier in utero (Segre et al., 1999). 
To elucidate further the transcriptional networks regulating this 
process, we examined the specifi  c role of Gata-3, the most 
highly expressed member of the GATA family of transcription 
factors in interfollicular epidermis.
Results
Epidermal-speciﬁ  c deletion of Gata-3 
results in perinatal lethality because 
of selective barrier impairment
GATA-3 expression in interfollicular epidermis is fi  rst  de-
tected in the immediate suprabasal layer at E15.5 (Fig. 1 A). 
At E16.5 and thereafter, GATA-3 is expressed in both basal and 
immediate suprabasal layers (Fig. 1 A). Gata-3−/− embryos 
die at E11 (Pandolfi   et al., 1995), and pharmacologic rescue of 
these embryos until E17.5 revealed a role for Gata-3 in devel-
opment of the inner root sheath of the hair follicle (Kaufman 
et al., 2003). To elucidate the necessary function of GATA-3 
in terminal stages of epidermal differentiation in vivo, we used 
the cre–loxP system. To generate mice with an epidermal-
specifi  c targeted ablation of Gata-3, homozygous fl  oxed Gata-3 
(Gata-3
fl  /fl  ) mice were crossed with mice heterozygous for a dele-
tion of Gata-3 (Gata-3
+/−) and expressing the Cre recombinase 
under the control of the K14 promoter (K14-Cre) to generate 
mice with a Gata-3
fl  /− K14-Cre genotype, hereafter referred to 
as Gata-3 mutants (Pai et al., 2003; Andl et al., 2004). Quanti-
tative PCR of amplicons both within and outside the Gata-3 
locus on mutant and control littermate epidermal genomic DNA 
demonstrated that >97% of the epidermal cells had deleted 
the Gata-3 locus (unpublished data). The residual amplifi  ca-
tion in Gata-3 mutants may be from melanocytes or Lang-
erhans cells, resident in the epidermis. Deletion of GATA-3 
mRNA and protein was also demonstrated by Northern and 
immunohistochemical analysis of Gata-3 mutant newborn skin 
(Fig. 1, B and C).
Gata-3 mutants, born at the expected Mendelian ratio, are 
distinguishable from their littermates at birth by a lack of prom-
inent whiskers. In the perinatal period, Gata-3 mutants do not 
feed and can be identifi  ed by the lack of a typical “milk spot.” 
Equally striking is the apparent desiccation of the Gata-3 mu-
tant skin during the perinatal period, which takes on a thin, 
  erythemic, wrinkled appearance (Fig. 2 A). During the fi  rst 6 h 
after birth, Gata-3 mutant mice lose an average of 5% of their 
birth weight. By comparison, littermates who do survive >24 h 
when unfed do not appear to desiccate and lose signifi  cantly 
less weight during a comparable period (Fig. 2 B). Specifi  cally, 
individual Gata-3 mutants lose weight at a rate that is >3.5- and 
7.8-fold greater than the standard deviation of the control litter-
mates. Because other barrier-defi  cient animal models display 
a similar perinatal lethality, we tested this directly (Segre et al., 
1999; List et al., 2002).
As compared with control littermates, Gata-3 mutant new-
borns exhibit a signifi  cant increase in the rate of transepidermal 
water loss across their skin surface (P < 0.001; Fig. 2 C). 
The increase in the rate of transepidermal water loss and 
weight loss is of a similar order of magnitude (Fig. 2 B). Gata-3 
mutants’ impaired skin barrier is unable to retain water in the 
terrestrial ex utero environment, which results in dehydration 
and, ultimately, lethality. To complement the studies that mea-
sure water loss across the skin surface, we investigated Gata-3 
mutants’ competence to exclude percutaneous dye penetration. 
As previously shown, dye exclusion in control littermates (visu-
alized as white areas) initiates on the dorsal surface at approxi-
mately E16.5 and spreads ventrally, resulting in complete dye 
impermeability by E17.5. A transient delay of 0.5 d is observed 
in both the initiation and completion of the dye exclusion of the 
Gata-3 mutants (Fig. 2 D). Because the Gata-3 mutants are able 
to exclude dye penetration before birth, this delay does not ex-
plain the increased rate of transepidermal water loss and sub-
sequent lethality. However, the biophysical properties of the 
skin barrier that regulate the relative permeability of small mole-
cules, infectious agents, water, and gases across this surface are 
still poorly understood.
Figure 1.  Epidermal-speciﬁ  c deletion of Gata-3. (A) Expression of GATA-3 
at E15.5 in immediate suprabasal layer and at E16.5 in both basal and 
suprabasal layers. α6 marks the basement membrane of the epidermis. 
(B) Deletion of Gata-3 mRNA, shown by Northern blot of skin mRNA 
probed with Gata-3 and Gapdh cDNA. wt, wild type; mt, mutant. (C) Immuno-
ﬂ   uorescence of newborn epidermis, demonstrating deletion of GATA-3 
in the epidermis. Nuclei were stained with DAPI. Dotted lines mark the 
basement membrane. der, dermis; epi, epidermis. GATA-3 REGULATES DEVELOPMENT OF SKIN BARRIER • DE GUZMAN STRONG ET AL. 663
To determine which of the three known components of the 
barrier is disrupted in Gata-3 mutant newborns, we analyzed 
tight junctions, CEs, and lipid composition. Although total lipid 
content was similar, Gata-3 mutants exhibit a selective defect in 
lipid synthesis. Gata-3 mutants have a decreased level of gluco-
sylceramides and its derivative ceramide EOS (Fig. 2 E). 
Ceramide EOS is one of the precursors of sphingolipids, which 
interact with free lipids to organize the lipid lamellar structures 
in the stratum corneum (SC; Wertz and van den Bergh, 1998). 
Ultrastructural analysis of Gata-3 mutant skin, preserved to 
maintain lipid structures, revealed a paucity of lamellar bodies 
in the SC. In addition, these lamellar bodies contain only a few 
disorganized membrane leafl  ets and irregular vacuoles (Fig. 2 F). 
This analysis points to a specifi  c defect in lipid content and 
  organization underlying the selective barrier impairment. In 
contrast, the other two elements of the barrier appear normal. 
Specifi  cally, egression of a subcutaneously injected dye halted 
at occludin-positive structures, indicating that the tight junc-
tions in Gata-3 mutants are fully competent (Furuse et al., 2002; 
unpublished data). In addition, the CEs of the Gata-3 mutants 
appear normal: mature, plump, and rigid (unpublished data).
Differentiation defects 
in GATA-3–deﬁ  cient skin
To investigate the etiology of Gata-3 mutants’ barrier defect, 
we examined the histology, differentiation, and proliferation 
status of embryonic Gata-3 mutant skin. At E1 5.5, when GATA-3 
is initially expressed, the histology of Gata-3 mutant skin 
appears normal (Fig. 3 A). At E16.5, nuclei persisted in 
the   presumptive granular layer of Gata-3–defi  cient epidermis, 
  consistent with a differentiation defect and delay in barrier 
  acquisition (Fig. 2 D and Fig. 3 A). At E17.5, granular cells of 
Gata-3–defi  cient epidermis were properly enucleated and differ-
entiated, again consistent with overcoming the delay in acquiring 
a selective barrier (Fig. 2 D and Fig. 3 A). Gata-3 mutant new-
born epidermis appears thinner with a disorganized basal layer 
(Fig. 3 A). Immunohistochemical analysis of Gata-3–defi  cient 
newborn epidermis demonstrated that the structural proteins 
K14 (basal) and loricrin (granular) were expressed in the proper 
cell layer (Fig. 3 B). Ultrastructural analysis of the Gata-3 mu-
tant newborn epidermis revealed the absence of fi  laments that 
connect the keratohyalin granules (Fig. 3 C), again suggesting 
that the terminal differentiation program may be impaired.
Figure 2. Loss  of  Gata-3 in the epidermis re-
sults in perinatal lethality because of a selec-
tive barrier impairment. (A) Newborn Gata-3 
mutant (mt) mice possess thin, erythemic, wrin-
kled skin. wt, wild type. (B) Weight loss as a 
percentage of initial weight over time. The rate 
of weight loss of mutants 1 and 2 are >3.5 
and 7.8 standard deviations from the mean of 
the control littermates, respectively. The   asterisk 
indicates the point after which mutant 1 
expired. (C) Transepidermal water loss assay 
measured on ventral surface of the newborn. 
(D) Dye exclusion assay performed on E16.0–
E17.5 embryos. (E) Total epidermal lipid com-
ponent analysis. n = 4 mice per group. GSL, 
glycosylceramides; GLA, acylglycosylceramides; 
ASS, ceramide with short α-hydroxyacids 
(C16) amide linked to sphingosine; ASL, ce-
ramide with long α-hydroxyacids amide linked 
to sphingosine acylceramides long; NP, ce-
ramide with normal fatty acids amide linked to 
phytosphingosine; NS, ceramide with normal 
fatty acids amide linked to sphingosine; EOS, 
ceramide with long (C30–C34) ω-hydroxyacids 
amide linked to sphingosine and bearing ester-
linked linoleic acid on the ω-hydroxyl group; 
FS, free sterol; CH, cholesterol. (F) Electron mi-
crographs of a region between a granulocyte 
and corneocyte displaying distorted lamellar 
bodies with few disorganized leaﬂ  ets (arrows) 
and large, irregular vacuoles in the mutant as 
compared with densely packed membrane 
leaﬂ  ets (arrows) in the wild type. Bars, 0.2 μm.JCB • VOLUME 175 • NUMBER 4 • 2006  664
The rate of proliferation of Gata-3 mutant basal cells is similar 
to controls, as measured by BrdU immunohistochemistry and 
cell cycle FACS analysis (unpublished data).
To circumvent the perinatal lethality of Gata-3 mutants 
and investigate the role GATA-3 plays in epidermal  homeostasis, 
we grafted E18.5 Gata-3 mutant and control littermate skin 
onto nude mice. The gross morphology of grafted Gata-3 
mutant skin confi  rmed the previously reported role of Gata-3 
in hair follicle specifi  cation (Fig. 4; Kaufman et al., 2003). 
Previous studies have established that hyperproliferation and 
acanthosis (thickened epidermis) are compensatory responses to 
impaired epidermal barrier (Proksch et al., 1991). Histological 
analysis of the grafted Gata-3 mutant skin displayed both these 
hallmark features (Fig. 4). Gata-3 mutant epidermis is  10 cell 
layers thick, with an increase in K1-positive suprabasal cells, 
whereas both control grafted and hairless nude epidermis are 
approximately three to four cell layers thick (Fig. 4). Although 
proliferation was increased in the Gata-3 mutant epidermis, it 
was restricted to the basal cells (unpublished data). These graft-
ing studies suggest that Gata-3 mutant epidermis retains an in-
herent barrier defect that extends beyond the perinatal period.
Epidermal transcriptional pathways 
regulated by GATA-3 at E15.5, E16.5, 
and newborn
To identify the pathways of gene expression that are affected by 
the loss of GATA-3 during development, we analyzed microarray 
data from Gata-3 mutant and control littermate dorsal skin isolated 
from three distinct epidermal stages of development: (1) at E15.5, 
Figure 3.  Differentiation defects in Gata-3–deﬁ  cient epidermis. (A) Histology 
of E15.5, E16.5, E17.5, and newborn (NB) dorsal skin. epi, epidermis; 
der, dermis. (B) Immunohistochemical staining of newborn skin with K14 
(basal) and loricrin (granular). (C) EM of the upper granular layer. Arrows 
highlight the presence/absence of ﬁ  laments binding and connecting the 
keratohyalin granules. wt, wild type; mt, mutant.
Figure 4.  Differentiation defects and compensatory hyperproliferation in 
transplanted Gata-3–deﬁ  cient skin grafts. Histological and immunohisto-
chemical staining with K14 and K1. wt, wild type; mt, mutant; H&E, hema-
toxylin and eosin.GATA-3 REGULATES DEVELOPMENT OF SKIN BARRIER • DE GUZMAN STRONG ET AL. 665
the initial defect in barrier acquisition; (2) at E16.5, the com-
pensatory acquisition of barrier to exclude small molecules; and 
(3) at newborn, the selective barrier defi  ciency upon exposure to 
the terrestrial environment. This tripartite experiment enabled 
us to query the genes and pathways affected by GATA-3 that led 
to the delay in epidermal differentiation and the persistent lipid 
and barrier defect.
At all developmental stages, lipid synthesis and modifi  ca-
tion was identifi  ed as the most signifi  cant and commonly af-
fected pathway in the Gata-3 mutants, consistent with the lipid 
defect observed in these animals (Fig. 5). Down-regulated at all 
epidermal developmental stages are prostaglandin-endoperoxide 
synthase 1 (Ptgs1; greater than threefold), 1-acylglycerol 3 
phosphate O-acyltransferase 5 (Agpat5; greater than three- to 
ninefold), and sphingosine-1-phosphate phosphatase 1 (Sgpp1; 
greater than two- to fi  vefold). The family of Elongation of very 
long fatty acids–like (Elovl) genes, Elovl1, Elovl3, Elovl4, and 
Elovl6, encoding lipid biosynthetic proteins, is also down-
regulated in Gata-3 mutants.
To determine if genes in the lipid biosynthetic pathway 
are direct targets of GATA-3, we used a genomic approach. 
First, to identify potential cis-acting regulatory elements in the 
lipid genes, we performed a multispecies alignment of the hu-
man sequences compared with mouse, rat, and dog homologues. 
Between mouse and human,  5% of the genomic sequence is 
under positive selection; i.e., alignable and conserved (Waterston 
et al., 2002). Only one third of these regions are predicted to 
encode an exon of a gene. The other regions of alignment are 
postulated to encode RNA genes or regulatory elements. An 
example of the multispecies alignment of the proximal promoter 
and fi  rst intron of AGPAT5 with the program MultiPipMaker is 
shown in Fig. 6 A (Schwartz et al., 2003). MultiPipMaker iden-
tifi  es two blocks of noncoding sequence conservation: distal to 
the fi  rst exon and proximal to the second exon. To refi  ne this 
analysis, we used TRANSFAC to query whether GATA-3 bind-
ing sites were predicted within these blocks of conserved se-
quence, with a consensus binding sequence of G A T A/T A/G 
(Merika and Orkin, 1993; Wingender et al., 2000). Examination 
of the conservation tracks on the University California Santa 
Cruz genome web browser enabled us to rapidly determine 
whether these predicted GATA-3 sites are conserved between 
species. Examples of two highly conserved GATA-3 sites 
(GATTA and GATTG) as well as one not conserved (GATTc) 
and one sequence conserved only with dog (GATTA) are given 
in Fig. 6 B. Finally, to determine if GATA-3 binds in vivo to 
these sites, we immunoprecipitated chromatin with a GATA-3–
specifi  c antibody. Two overlapping amplicons (+0.9 and +1.0 
from AGPAT5 transcription start site), which contain these 
highly conserved GATA-3 binding sites, were specifi  cally en-
riched 3.8- and 3.2-fold in the GATA-3 chromatin immunopre-
cipitated DNA. Sequences in the proximal promoter (−0.2) and 
more distal in the AGPAT5 gene (+15.5 and +39.2) were not 
enriched in the GATA-3 chromatin immunoprecipitated DNA 
(Fig. 6 C). Although a similar genomic analysis of PTGS and 
SGPP1 were performed, we did not identify multispecies con-
served GATA-3 binding sites, which might suggest that the cri-
teria for inclusion were very stringent. In summary, GATA-3 
binds in vivo to a region in the fi  rst intron of the lipid acyltrans-
ferase gene AGPAT5 that contains highly conserved GATA-3 
binding sites.
In addition to the defects in lipid synthesis, Gata-3 mutants 
display a developmental delay in the expression of structural 
proteins (Fig. 7 A). Specifi  cally at E15.5, genes encoding the 
cornifi  cation proteins hornerin and loricrin, as well as the differ-
entiation proteins K1 and involucrin, are down-regulated in the 
Gata-3 mutants. At E16.5, expression of late CE genes (LCE 1B, 
2B, 2C, 3A, and 4B) are either absent or decreased by more than 
fi  vefold in the Gata-3 mutants, demonstrating a continuation of 
the differentiation delay. Previous work has shown that late CE 
protein expression immediately precedes in utero dye imperme-
ability in a patterned fashion (Marshall et al., 2001). Therefore, 
we postulate that this delay in late CE gene expression underlies 
the delay in barrier acquisition visualized in Fig. 2 D. Because of 
their temporal expression during development, the genes down-
regulated at E15.5 are different than E16.5, but both expression 
profi  les refl  ect a delay in differentiation. By the newborn stage, 
Gata-3 mutants express the vast majority of these genes  encoding 
epidermal differentiation and cornifi  cation proteins at normal 
levels. This transcriptional profi  ling provides the molecular 
  underpinnings to interpret the morphological changes in the 
Gata-3 mutant skin, observed during development.
The transcriptional profi  le of Gata-3 mutant newborn skin 
also refl  ects the pathways invoked to compensate in the ex utero 
Figure 5.  Lipid synthesis pathway is affected in Gata-3 mutants. Heat map 
representation of microarray data, which demonstrates down-regulation of 
genes involved in the lipid synthesis and modiﬁ  cation in Gata-3 mutants at 
E15.5, E16.5, and newborn (NB). Green indicates a more than twofold 
decrease in mutants, bright green indicates a more than ﬁ  vefold decrease in 
mutants, and black indicates no change between mutants and wild type.JCB • VOLUME 175 • NUMBER 4 • 2006  666
terrestrial environment for an intrinsic barrier defect. Classic 
studies have shown that barrier defi  ciency results in increased 
DNA synthesis and acanthosis (Proksch et al., 1991). Gata-3 
mutants express high levels of K6 in the suprabasal layers of the 
interfollicular epidermis (unpublished data), consistent with many 
other examples of K6/K16 in hyperproliferative conditions 
(Wong and Coulombe, 2003). Repetin is a fi  laggrin-like protein 
that has been postulated to specifi  cally aggregate K6/K16 
 fi laments, explaining its expression under these conditions (Pre-
sland et al., 2006). Unexpectedly, Gata-3 mutants express K13 
protein in the spinous layer of the epidermis (Fig. 7 B). K13 is 
normally expressed only in stratifi  ed but not cornifi  ed epithe-
lium, such as tongue and esophagus. K13 expression in epider-
mis has previously only been reported in papillomas at high 
risk of converting to squamous cell carcinoma (Nischt et al., 
1988). The expression of K13 could suggest a role for GATA-
3 in squamous cell carcinoma progression. Alternatively, K13 
expression could refl  ect a similar underlying state of the skin 
that is common to both barrier impairment and tumor progres-
sion, such as mounting an infl  ammatory response.
The fi  rst line of cutaneous defense against infection 
by microorganisms is the proteinaceous/lipid skin barrier. 
Augmenting this physical barrier are both the innate and adap-
tive immune systems (Zasloff, 2002; Braff et al., 2005; Lehrer, 
2005). Antimicrobial peptides, effectors of innate immunity, are 
expressed by keratinocytes and have distinct but overlapping 
reactivity against bacteria, fungi, and enveloped viruses (Braff 
et al., 2005). Antimicrobial peptides are induced to provide 
a rapid defense, which is particularly important in fetal skin 
Figure 6.  GATA-3 binds in vivo to sites in the 
ﬁ  rst intron of the lipid acetyltransferase gene 
AGPAT5. (A) Comparison of human AGPAT5 
sequence (−2 kb upstream of transcription 
start site to second exon) with mouse, rat, and 
dog Agpat5 sequences. MultiPipMaker calcu-
lates the percentage of identity using a Blastz 
alignment. Percentage of identity (50–100%) 
is shown on the y axis. Exons 1 and 2 are 
marked above the sequence identity plot with 
ﬁ   lled boxes. (B) Location of ChIP amplicons, 
in proximal promoter (−0.2), in region of 
sequence conservation distal to exon 1 (+0.9 
and +1.0) and in region of sequence conser-
vation proximal to exon 2 (+15.5) with posi-
tions relative to AGPAT5 transcription start site. 
Overlap between +0.9 and +1.0 amplicons 
(Chr8:6,554,370-6,544,430) contains four 
GATA-3 binding sites (boxed). (C) C hIP dem-
onstrates speciﬁ  c binding of GATA-3 in vivo 
to region distal to exon 1 in the ﬁ  rst intron 
of AGPAT5.
Figure 7.  Delayed differentiation during embryonic development and 
  aberrant keratin 13 expression in Gata-3 mutant newborns. (A) Heat map 
representation of microarray data, demonstrating delayed expression of 
epidermal differentiation proteins at E15.5 and E16.5. Newborn (NB) 
Gata-3 mutants display aberrant expression of epidermal structural 
  proteins. Green indicates a more than twofold decrease in mutants, bright 
green indicates a more than ﬁ  vefold decrease in mutants, red indicates a 
more than twofold increase in mutants, bright red indicates a more than 
ﬁ  vefold increase in mutants, and black indicates no change between mu-
tants and wild type. LCE, late CE genes. (B) Immunohistochemical staining 
of K13 in newborn skin. b, basal; sp, spinous; gr, granular. GATA-3 REGULATES DEVELOPMENT OF SKIN BARRIER • DE GUZMAN STRONG ET AL. 667
before maturation of immunological memory (Marchini et al., 
2002). Epithelial defense is a signifi  cantly affected pathway in 
Gata-3 mutant newborns, including a strong up-regulation of 
the antimicrobial peptides, secretory leukocyte proteinase in-
hibitor, adrenomedullin, S100A8, S100A9, and β-defensin 1 
and 3 (Fig. 8; Braff et al., 2005; Lehrer, 2005).
To investigate the specifi  city of the transcriptional profi  le 
of Gata-3 mutant newborn skin, we compared these results with 
a similar analysis of barrier-impaired Klf4−/− skin (Segre et al., 
1999). First, the levels of Klf4 are not altered in Gata-3 mutants 
and vice versa, suggesting that these transcription factors 
are not epistatic but distinct in their regulation of epidermal 
  differentiation (unpublished data). Second, the nature of the 
barrier defi  ciencies in Klf4−/− and Gata-3 mutants appears 
completely distinct. Klf4−/− mutants exhibit a specifi  c defect 
in CE maturation, with normal synthesis but abnormal extrusion 
of lipids, and a persistent dye penetration even as newborns. 
Molecularly, Ptgs1 is the only “lipid synthesis pathway” gene 
with decreased levels in Klf4 mutants. Both mutants do up-
  regulate genes common to a hyperproliferative state, including 
K6, K16, and repetin. However, the greatest similarity between 
the two barrier-defi  cient mutant mice is an up-regulation of the 
epithelial defense genes. Klf4−/− and Gata-3 mutants show a 
similar up-regulation of the innate immune effectors, secretory 
leukocyte proteinase inhibitor and β-defensin 3 (Fig. 8). 
However, whereas Klf4−/− mutants show a strong up-regulation 
of β-defensin 6, Gata-3 mutants more strongly up-regulate ad-
renomedullin, S100A9, S100A8, and β-defensin 1. Thus, Gata-3 
and Klf4 mutants, genetically distinct models of barrier impair-
ment, both activate an innate immune response, but they do so 
through up-regulation of distinct antimicrobial peptides.
Discussion
These results demonstrate Gata-3’s specifi  c role in epidermal 
barrier acquisition. Gata-3 mutant embryos exhibit a transient 
delay in differentiation, demonstrated by percutaneous dye 
penetration. Similar delays in dye exclusion were observed in 
mice with targeted deletions of genes encoding CE proteins, 
envoplakin, and loricrin (Koch et al., 2000; Maatta et al., 
2001). However, envoplakin- and loricrin-defi  cient mice sur-
vive the perinatal period, perhaps because of the compensatory 
up-  regulation of other structural proteins. In contrast, Gata-3 
defi  ciency in the epidermis results in a perinatal lethality with an 
inherent barrier defect that extends postnatally, as demonstrated 
by grafting experiments. Underlying Gata-3 mutant’s barrier 
defect is a severe defect in lipid synthesis, in particular, ce-
ramide EOS and glucosylceramides. The electron micrographs 
of Gata-3 mutant skin, postfi  xed to maintain lipid structure, are 
reminiscent of similar fi  ndings in infants with severely affected 
type 2 Gaucher disease. Mutations in β-glucocerebrosidase, 
the enzyme that catalyzes the hydrolysis of glucosylceramide 
to ceramide, underlie Gaucher disease (Sidransky et al., 1992). 
Type 2   Gaucher disease and a mouse model, with a targeted 
deletion of β-glucocerebrosidase, manifest at birth with a pri-
mary barrier defi  ciency and display abnormal loosely packed 
lamellar body–derived sheets in the SC (Holleran et al., 1994). 
Our fi  ndings suggest that GATA-3 may act to regulate this im-
portant process of lipid biosynthesis, and genes in this pathway 
should be tested as a potential modifi  ers to explain the wide 
phenotypic variation observed among Gaucher patients (Goker-
Alpan et al., 2005). Our studies identifi  ed AGPAT5, which cata-
lyzes an essential step in the synthesis of all glycerolipids, as a 
direct target in vivo for GATA-3 (Lu et al., 2005). Future studies 
will address the hierarchical transcriptional regulation of lipid 
synthesis in the skin.
Morphological and transcriptional analyses at distinct de-
velopmental stages revealed both GATA-3’s regulation of dif-
ferentiation and lipid synthesis pathways and the compensatory 
responses to impaired barrier. For example, although the new-
born barrier-defi  cient Gata-3 mutant skin is hypocellular, the 
grafted Gata-3 mutant skin is acanthotic or hypercellular, as 
a compensatory response to the impaired barrier in the terrestrial 
environment (Fig. 3 A and Fig. 4). Analysis of Gata-3 mutants 
at only one developmental stage would have revealed the spe-
cifi  c defect in lipid biosynthesis but would have been refractive 
to elucidating the transient delay in expression of genes en-
coding differentiation and cornifi  cation proteins. Transcriptional 
profi   ling at multiple developmental stages brings clarity to 
pathways affected by and responding to Gata-3’s loss.
This process is remarkably well conserved, as GATA tran-
scription factors are also essential to specify the fate and regu-
late differentiation of epidermal cells in Caenorhabditis elegans. 
Figure 8.  Innate immunity is evoked in both newborn Gata-3 and Klf4−/− 
mutant skin. (A) Heat map representation of microarray data,   demonstrating 
speciﬁ   c increased expression of genes encoding antimicrobial proteins, 
  effectors of innate immune, in both Gata-3 and Klf4−/− mutant newborn 
skin. Black indicates no change; dark red indicates >1.3-fold up-regulated; 
red indicates >1.5-fold up-regulated; and bright red indicates >2.5-fold 
up-regulated in mutants. (B) Quantitative PCR conﬁ  rmation of genes en-
coding antimicrobial peptides up-regulated in Gata-3 and Klf4−/− mutant 
newborn skin. β2m, β-2-microglobulin for normalization. wt, wild type.JCB • VOLUME 175 • NUMBER 4 • 2006  668
The cell biology of the C. elegans epidermis closely resembles 
that of mammals, including intermediate fi  lament networks and 
cell connections through adherens and tight junctions (Hardin 
and Lockwood, 2004). GATA transcription factor ELT-1 speci-
fi  es epidermal cell fate (Page et al., 1997). Subsequently, ELT-5 
and -6 (adjacent genes encoding GATA factors) are required 
throughout development to regulate epidermal cell differentiation 
(Koh and Rothman, 2001).
Mammalian lung and skin are both epithelia at the inter-
face between the body and the environment that form protein-
aceous lipid barriers. Although lung is a branched simple 
epithelium and the composition of the barriers is distinct, there 
are remarkable similarities between the systems. At the tran-
scriptional level, corticosteroids and thyroid hormone  accelerate 
barrier maturation in utero of both epidermis and alveoli 
  (Aszterbaum et al., 1993). Just as Klf4 is necessary for the ter-
minal stages of epidermal development, Lklf (Klf2) plays an im-
portant role in the terminal stages of lung development (Wani 
et al., 1999). GATA-6 is the only known GATA factor expressed 
in the distal epithelium of the developing lung. Expression of a 
dominant-negative form of GATA-6 in these alveolar cells re-
sulted in a defect in terminal differentiation and proximal air-
way development. These GATA-6 transgenic mice die perinatally 
with defects in lipid (surfactant protein) synthesis and decreased 
expression of Aquaporin 5, a gene encoding a water channel. 
Similar to GATA-3’s role in epidermal barrier, GATA-6 is nec-
essary for maturation of the proteinaceous lipid barrier that 
regulates alveoli gas exchange (Yang et al., 2002).
Extending the well-established paradigms from hemato-
poietic cells, it is intriguing to speculate whether GATA-3 will 
have similar interactions with family members of other tran-
scription factors in the skin. GATA-1 acts upstream of EKLF 
(KLF1) during erythroid development, and GATA-3 acts up-
stream of LKLF (KLF2) during lymphocte development (Kuo 
and Leiden, 1999; Anderson et al., 2000). The expression of 
GATA-3 and KLF4 in basal and suprabasal cells, respectively, 
is consistent with GATA-3 acting upstream of KLF4. Klf4 levels 
are unchanged in Gata-3 mutants, which could refl  ect compen-
satory autoregulation or parallel pathways.
Both Klf4 and Gata-3 mutants exhibit an epidermal bar-
rier defi  ciency, but each activates distinct antimicrobial pep-
tides, effectors of innate immunity. Innate immunity is important 
before the adaptive immune system mounts a response and 
  particularly during the fi  rst year of human life, as the adaptive 
immune system is maturing. These fi  ndings demonstrate that new-
born skin can mount a robust activation of an innate immunity. 
Moreover, an analysis of Gata-3 and Klf4 mutant newborns 
demonstrates that genetically distinct barrier impairments acti-
vate overlapping but distinct innate immune responses. The 
comparison of Klf4- and Gata-3–defi  cient newborn epidermis 
will be very informative to unravel the complex immune 
response to barrier impairment.
Barrier disruption is a hallmark characteristic of common 
infl  ammatory skin disorders, such as atopic dermatitis (more 
commonly known as eczema) and psoriasis (Segre, 2006). Recent 
work has examined the distinct innate immune responses of 
psoriasis and atopic dermatitis (de Jongh et al., 2005). In particular, 
patients with atopic dermatitis have an increased tendency to 
develop both disseminated viral skin infection after smallpox 
vaccine inoculation and recurrent Staphylococcus aureus 
infections because of inadequate innate immune response 
(Howell et al., 2006). In contrast, barrier-impaired keratitis-
ichthyosis-deafness patients develop recurring Candida albicans 
yeast infections. Mutations in the epidermal cornifi  cation protein 
fi  laggrin were recently reported to underlie atopic dermatitis, 
focusing attention on the role that barrier impairment plays in 
this disorder (Palmer et al., 2006). Because of the naive state of 
T and B cells in newborn mice, a full investigation into this 
complex innate/adaptive immune response requires adult 
epidermal-specifi  c targeting of Gata-3 and Klf4.
Materials and methods
Generation of Gata-3
ﬂ  /ﬂ   K14-Cre mice and skin grafts
Mice carrying the Gata-3
ﬂ   allele (Pai et al., 2003) were crossed with mice 
expressing germline Cre recombinase (Scheel et al., 2003) to generate a 
Gata-3
− allele. These mice were then crossed onto mice transgenic for 
human K14-driven Cre recombinase (Andl et al., 2004) to generate 
Gata-3
+/− K14-Cre. Gata-3
−/ﬂ   K14-Cre mice were generated by crossing 
Gata-3
ﬂ  /ﬂ   mice with Gata-3
+/− K14-Cre mice. Genotyping was done as 
previously described (Pai et al., 2003; Andl et al., 2004). The morning of 
the plug was 0.5 d after coitum. E18.5 dorsal skin was grafted onto nude 
mice in an area that the mice could not scratch, and these mice were indi-
vidually housed. All animal studies were approved by the National Human 
Genome Research Institute animal care and use committee, and all mice 
were housed in our Association for Assessment of Laboratory Animal 
Care–accredited facility.
Barrier function assays
Dye penetration assays were performed with X-gal at pH 4.5 for 4 h at 
37°C as previously described (Hardman et al., 1998). After staining, em-
bryos were photographed under a dissecting scope (MZFLIII; Leica) using 
a digital camera (AxioCam; Carl Zeiss MicroImaging, Inc.), and images 
were acquired with OpenLab software (Improvision). Transepiderrmal 
water loss was measured using a Tewameter (Courage + Khazaka).
Histology and immunohistochemistry
Routine histology and parafﬁ  n staining were performed as described previ-
ously (Jaubert et al., 2003). For immunoﬂ  uorescence, frozen sections were 
ﬁ  xed in 10% formalin/PBS and stained with primary antibodies: rabbit 
polyclonal antibodies against GATA-3 (Segre 379-2b; 1:100), K14 
(1:1,000; Covance,), K1 (1:1,000; Covance), Loricrin (1:500; Covance), 
K13 (1:500; a gift from S. Yuspa, National Cancer Institute, Bethesda, MD), 
and α6 integrin rat polyclonal antibodies (MAB1982; 1:100; Chemicon). 
Fluorescent secondary antibodies were Alexa 488 goat anti–rabbit 
(1:400) and Alexa 594 goat anti–rat (1:200). Slides were mounted with 
DAPI glycerol media, containing SlowFade Gold antifade, to counterstain 
nuclei (Invitrogen). Fluorescent staining was imaged with a microscope 
(Axioplot; Carl Zeiss MicroImaging, Inc.) and photographed with a camera 
(CoolSNAP; Photometrix).
RNA isolation, Northern blot analysis, and microarray
RNA was isolated from the dorsal skin of newborns and embryos, incubated 
in RNALater (Ambion), snap frozen, homogenized in TRIzol (Invitrogen) 
  using tissue lyser (QIAGEN), and processed according to the manufacturer’s 
instructions. Northern blot was hybridized with probes for Gata-3 and 
Gapdh. Microarrays were done on independent samples for newborns 
(n = 4) and E15.5 and E16.5 embryos (n = 3). Control littermates are 
Gata-3
ﬂ  /+ or Gata-3
ﬂ  /ﬂ  , and mutant mice are Gata-3
ﬂ  /− K14-Cre. Compli-
mentary RNA was labeled according to the manufacturer’s recommenda-
tions and hybridized onto Affymetrix 430 2.0 A+B mouse arrays. These 
arrays contain 45,000 probe sets, representing 34,000 well-substantiated 
mouse genes. We identiﬁ  ed  20,000 probes as present in mouse skin dur-
ing the developmental windows analyzed in these experiments. Microarray 
results were analyzed by Genesifter using a t test (P < 0.05) and Benjamini 
and Hochberg correction (VizX Labs). Conﬁ  rmation of fold changes was 
made with quantitative PCR on cDNA from Gata-3 and Klf4 mutants on a GATA-3 REGULATES DEVELOPMENT OF SKIN BARRIER • DE GUZMAN STRONG ET AL. 669
TaqMan light cycler (Applied Biosystems) with SYBR Green mix (Invitrogen), 
and primers spanning exon boundaries are listed in Table S1 (available at 
http://www.jcb.org/cgi/content/full/jcb.200605057/DC1).
Genomic analysis
Pipmaker and MultiPipmaker were performed with repeat masked 
sequences (http://pipmaker.bx.psu.edu/pipmaker/) with mouse 
(Chr8:18,841,481-18,861,523), human (Chr8:6,548,286-6,569,868), 
rat (Chr16:75,769,607-75,791,434), and dog (Chr16:61,666,596-
61,692,310) sequences (Schwartz et al., 2003). Coordinates for blocks 1 
and 2 are human (Chr8:6,553,816-6,554,997 and Chr8:6,568,473-
6,569,799, respectively). The overlap of amplicon +0.9 and +1.0 in 
which the GATA-3 conserved sequences are identiﬁ  ed is Chr8:6,554,370-
6,544,430. Mouse and human sequence coordinates are relative to 
February 2006 and March 2006 releases, respectively. TRANSFAC was 
accessed through a National Human Genome Research Institute site license 
(Wingender et al., 2000).
Chromatin immunoprecipitation (ChIP) studies
ChIP was performed on human MCF-7 cells, an epithelial cell line that 
expresses GATA-3 and the lipid biosynthetic genes, including AGPAT5. 
Chromatin was immunoprecipitated with a GATA-3 antibody (SC-9009; 
Santa Cruz Biotechnology, Inc.) binding to the endogenous protein. Other 
reagents were provided in the ChIP-IT kit (Active Motif), and we followed 
the manufacturer’s instructions. DNA/GATA-3 antibody complexes were 
immunoprecipitated with protein G and A beads. DNA was quantiﬁ  ed 
with QuantiTect SYBR Green PCR kit (QIAGEN). Primers are listed in Table S2 
(available at http://www.jcb.org/cgi/content/full/jcb.200605057/DC1), 
and amplification was quantified on a TaqMan light cycler (Applied 
  Biosystems). Binding of GATA-3 to chromatin immunoprecipitated DNA 
was   measured as the change in the number of cycles required to cross a 
threshold, normalized to sonicated, reverse-cross-linked input DNA.
Ultrastructural and lipid analysis
Whole backskin was removed, placed on a paper towel, and ﬁ  xed  in 
modiﬁ  ed Karnovsky’s ﬁ  xative (2% paraformaldehyde, 2% glutaraldehyde, 
0.1 M cacodylate buffer, pH 7.3, and 0.06% CaCl2) overnight at 4°C. 
Samples were washed twice in 0.1 M cacodylate buffer after ﬁ  xation be-
fore embedding. Lipids were extracted into chloroform: methanol mixtures 
and analyzed by thin-layer chromatography as previously described (Law 
et al., 1995). Lipid masses were used to calculate weight percentages. 
Ruthenium tetroxide transmission EM was performed as previously described 
(List et al., 2003).
Online supplemental material
Tables S1 and S2 provide the sequences of the primers used for quantita-
tive RT-PCR and ChIP, respectively. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200605057/DC1.
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